Lactulose - 1 A Pharma

Quick links

Choose a section

Quick links to important sections

Advertisements

Lactulose - 1 A Pharma

Advertisements
Advertisements

Overview of Lactulose - 1 A Pharma

Quick Facts: Lactulose - 1 A Pharma Identity

Property Description
Active ingredient Lactulose
Form Oral Solution or Syrup
Pharmacological class Osmotic Laxative
Common use Promoting bowel regularity
Origin Synthetic Disaccharide

Identity and Classification: What Type of Medicine is Lactulose - 1 A Pharma?

Lactulose - 1 A Pharma is a medicinal product classified as an osmotic laxative, with the single active ingredient being the synthetic sugar, Lactulose. This compound is recognized on the Model List of Essential Medicines. The medication is a monopreparation and belongs to the A06AD11 segment of the Anatomical Therapeutic Chemical (ATC) classification system. Lactulose is chemically defined as 4-O-\beta-D-galactopyranosyl-D-fructofuranose, a synthetic disaccharide designed to be minimally absorbed from the upper gastrointestinal tract, ensuring its action occurs locally in the colon.

Composition and Form: What is Lactulose - 1 A Pharma Made of?

Lactulose - 1 A Pharma is typically presented as an oral solution or syrup, which is a liquid formulation intended for administration by mouth. The preparation consists primarily of the active ingredient, Lactulose, dissolved in an aqueous solution base. The final product may contain minor amounts of other related sugars, specifically Lactose, Galactose, and Fructose, which are residual components from the synthesis process. The liquid form facilitates convenient oral administration and is often preferred for managing issues in patient groups such as children or the elderly who require easier ingestion compared to solid forms.

Primary Purpose: What General Benefit Does Lactulose Provide?

The primary general purpose of Lactulose is to promote bowel regularity and relieve discomfort by softening the stool. As an osmotic agent, it functions by drawing water into the large intestine, increasing both the fluid content and the volume of the stool. This medicine helps to hydrate the stool, making it easier to pass. This mechanism is clinically recognized for providing gentle, effective relief in scenarios like chronic functional constipation.

Furthermore, when intestinal bacteria break down Lactulose, the resulting acidification of the colon provides a specialized secondary benefit: it helps to "trap" neurotoxins like ammonia in the stool for excretion. Lactulose reduces the amount of ammonia in the blood by trapping it in the colon.

Regulatory References

  1. World Health Organization (WHO) on the Model List of Essential Medicines
  2. U.S. National Institutes of Health (NIH) notes
Advertisements

What side effects are possible with Lactulose - 1 A Pharma?

Possible side effects and safety information

The safety profile of Lactulose - 1 A Pharma is defined by adverse reactions primarily affecting the gastrointestinal tract, as classified in official regulatory documents. Side effects are officially categorized by the frequency of their occurrence:


Regulatory Classification of Adverse Reactions

Frequency Classification System-Organ Class Examples of Documented Effects
Very Common (ge 1/10) Gastrointestinal disorders Diarrhoea
Common (ge 1/100 to <1/10) Gastrointestinal disorders Flatulence, Abdominal pain, Nausea, Vomiting
Uncommon (ge 1/1,000 to <1/100) Investigations Electrolyte imbalance
Not Known (Frequency cannot be estimated) Immune/Skin disorders Hypersensitivity reactions, Rash, Pruritus, Urticaria

Safety Patterns and Constraints

Time and Dose-Related Effects: The official label notes that flatulence may occur during the first few days of treatment but typically resolves thereafter. The occurrence of diarrhoea or abdominal pain is explicitly stated as an indicator that the dosage may be too high. The development of electrolyte imbalance is associated with the long-term, chronic use of unadjusted high doses.

Serious Safety Consideration: The most significant documented safety concern is the potential for electrolyte imbalance (e.g., low potassium) following severe, persistent diarrhoea caused by high-dose exposure.

Specific Safety Constraints: Lactulose is contraindicated in individuals with pre-existing gastro-intestinal obstruction or Galactosaemia. Additionally, periodic control of serum electrolytes is indicated for elderly or debilitated patients if treatment continues for more than six months, as specified in regulatory documents. These classifications structure the official understanding of the medicine’s risk profile.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official overdose information for Lactulose - 1 A Pharma is centered on an exaggeration of its intended effects, leading to specific gastrointestinal distress and a mandatory need to monitor for resulting systemic complications.

Overdosage, typically from high doses or chronic misuse, primarily affects the Gastrointestinal and Metabolic/Electrolyte systems.

Overdose Presentation Severe Outcome & Management
Documented Manifestations Diarrhoea (primary sign)
Abdominal pain and abdominal cramps
Required Emergency Action Seek correction of electrolyte disturbances
Immediately stop treatment or reduce dose
Severe Outcomes Electrolyte Imbalance (Hypokalemia, Hypernatremia)
Extensive fluid loss and dehydration

When to Seek Urgent Medical Help:

Urgent medical attention is required if severe or prolonged diarrhoea and/or vomiting occurs, leading to a suspected or actual electrolyte imbalance. The treatment, which includes symptomatic management, must focus on correcting these disturbances.

Population-Specific Considerations:

Regulatory documents note that elderly patients and individuals with conditions like renal or hepatic impairment are particularly prone to developing the serious electrolyte disorders associated with overdose. For these at-risk patients on long-term therapy, periodic control of electrolytes is indicated.

No specific antidote is documented as available for lactulose overdose.

Advertisements

Therapeutic Uses of Lactulose - 1 A Pharma

What Lactulose - 1 A Pharma treats: main uses and benefits

Lactulose is a therapeutic solution used across two primary domains: the management of symptoms related to chronic constipation and addressing conditions involving episodic manifestations, such as hepatic encephalopathy (HE).

Constipation

For constipation, lactulose is used for managing symptoms that interfere with daily comfort, including infrequent bowel movements and hard stools. It provides long-term symptomatic support, and its action helps address physical discomfort. This contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Hepatic Encephalopathy (HE)

In the more critical context of hepatic encephalopathy, this condition involves episodic or fluctuating manifestations related to systemic imbalance. Lactulose assists with managing symptoms associated with acute or disruptive episodes of systemic imbalance. Its use is applied in addressing conditions marked by temporary physiological imbalance, which supports the patient during difficult episodes by easing distress. The primary therapeutic areas covered are constipation and assisting with the symptoms linked to organ-specific functional stress in HE.

“Its use is applied in addressing conditions marked by temporary physiological imbalance, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Lactulose - 1 A Pharma?

This medicine's eligibility is strictly determined by regulatory contraindications and patient status.

Contraindicated Populations (Must Not Use)

Condition/Group Status
Galactosaemia (a hereditary disorder) Absolute Contraindication
Gastrointestinal obstruction or digestive perforation/risk (e.g., acute inflammatory bowel disease) Absolute Contraindication
Hypersensitivity to lactulose or excipients Absolute Contraindication
Rare hereditary problems of galactose/fructose intolerance or total lactase deficiency Contraindication

Special Population Eligibility

Population Group Regulatory Status
Pregnancy and Breastfeeding Permitted (due to negligible systemic exposure)
Children/Infants Use should be exceptional and under medical supervision
Children with Hepatic Encephalopathy (HE) Safety and efficacy not established; no dosage recommendations exist

Eligibility-Related Restrictions

Patients with Diabetes Mellitus should note the sugar content in high doses (for HE). Patients prone to electrolyte disorders (e.g., elderly on long-term use) and those with lactose intolerance require special caution and monitoring.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information regarding Lactulose interactions is based on its local, non-systemic activity and influence on the colonic environment.

Documented Interaction Patterns

Interactions primarily concern two areas: the risk of hypokalaemia (potassium loss) and interference with the colonic environment ( pH).

Interaction Type Interacting Products / Classes Effect as Documented by Regulators
Potassium Loss Risk (Pharmacodynamic) Thiazide diuretics, Corticosteroids, Amphotericin B Increased risk of potassium loss, which can potentiate the effects of cardiac glycosides (e.g., Digoxin).
Reduced Efficacy (Physicochemical) Non-absorbable Antacids, Oral Anti-infective Agents (e.g., Neomycin) May inhibit the necessary Lactulose-induced drop in colonic pH, potentially reducing efficacy.
Efficacy Reduction of Co-drugs pH-dependent colonic-release medicines (e.g., 5-ASA) Lactulose may reduce the efficacy of these co-administered drugs by lowering the colonic pH required for their release.

Interaction-Related Constraints and Special Cautions

  • Indication-Specific Restriction: The co-administration of other laxatives must be avoided when Lactulose is used for hepatic encephalopathy ( HE) to ensure accurate dose titration.
  • Procedural Precaution: Patients undergoing electrocautery during proctoscopy or colonoscopy require thorough bowel cleansing with a non-fermentable solution due to a documented theoretical hazard of intestinal gas accumulation.
  • Long-Term Monitoring: For elderly or debilitated patients on therapy exceeding six months, periodic measurement of serum electrolytes (e.g., potassium) is officially advised.
Advertisements

Mechanism of Action

How Lactulose - 1 A Pharma Works

Lactulose works locally within the large intestine by initiating two distinct mechanistic consequences, both resulting from its primary action as a non-absorbed sugar substrate for gut bacteria.


Targeting Colonic Bacteria for Acid Production

Lactulose is not digested by human enzymes, reaching the colon intact where the gut microbiota (colonic bacteria) break it down through fermentation. This process generates low molecular weight organic acids (like lactic and acetic acid). This action represents a substrate-driven enzymatic cascade that lowers the pH level within the colon.


Osmotic and Motility Modulation

The presence of the non-absorbed molecules and the newly formed organic acids raises the osmotic pressure inside the colon, drawing water into the intestinal lumen. This increased water content and volume of the stool mass results in physical distention. This distention and the acidic pH mildly stimulate the natural muscular contractions (peristalsis), influencing the frequency and ease of defecation through osmotic and propulsive action.


pH-Dependent Ammonia Trapping

The acidic environment created by the bacterial fermentation (low pH) is crucial for a second effect. It causes the chemical conversion of lipid-soluble, absorbable ammonia ( NH3) into non-absorbable ammonium ions ( NH4^+). This ion-trapping mechanism prevents the reabsorption of ammonia into the bloodstream, thereby contributing to a reduction in the level of the metabolite in the systemic circulation.

Advertisements

Dosage and Administration Information

How to Use Lactulose - 1 A Pharma

The usage of Lactulose oral solution is defined by specific administration guidelines, dosing protocols, and required adjustments. The medication is primarily administered via the oral route for all approved uses. However, for the initial management of Hepatic Encephalopathy (HE), an alternative rectal route is specified for rapid action.


Dosing and Frequency Principles

Lactulose may be taken as a single daily dose or divided into two or three doses per day. If a single daily dose is utilized, it is generally recommended to be taken at the same time each day.

Indication Adult Starting Dose Range (Oral) Adult Maintenance Dose Range (Oral)
Chronic Constipation 15 mL to 45 mL daily (10 g to 30 g) 15 mL to 30 mL daily (10 g to 20 g)
Hepatic Encephalopathy (HE) 30 mL to 50 mL three to four times daily Titrated to achieve 2-3 soft stools per day

The dose for HE is continually titrated (adjusted) to meet the target stool output, a procedural step that ensures the correct amount is used. The effect may require 24 to 48 hours to manifest, defining the expected onset of the treatment course.


Administration Conditions and Requirements

For precise dosing, the solution must be measured using a specially marked measuring device and not a household spoon. The solution may be taken undiluted or mixed with other liquids like water, milk, or juice. During the course of treatment, it is necessary to maintain sufficient fluid intake (1.5 L to 2 L daily) as a key supportive measure.

Specific pediatric dosing regimens are established for different age groups. For other populations, such as older adults or those with renal or hepatic impairment, no special dosage recommendations are noted for the treatment of constipation.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Lactulose - 1 A Pharma


Research Evidence for Chronic Constipation

The research into Lactulose for constipation is primarily based on Randomized Controlled Trials (RCTs), which involve comparison groups, such as inactive controls or other active agents. These studies have been used in research exploring how symptoms change over time in individuals dealing with functional constipation. The research examined measurements related to stool frequency and stool consistency.

Studies report observed measurements of how outcomes evolved in the studied populations. Patient-reported outcomes and overall quality of life were also monitored. Despite the volume of research, evidence quality varies across studies, particularly in large pooled analyses, and direct comparison to an inactive treatment in modern, large trials remains limited.

Research Evidence for Hepatic Encephalopathy (HE)

Lactulose was studied for the management of conditions characterized by fluctuating or episodic manifestations, specifically Hepatic Encephalopathy (HE). The evidence for this use is derived from RCTs, systematic reviews, and meta-analyses. These studies focused on measuring patient metrics during acute or disruptive episodes and also in settings related to recurrence.

The research examined measurements related to clinical status, blood biomarkers (e.g., ammonia levels), and, in some cases, overall survival rates. Studies monitored changes in these metrics and tracked patterns related to HE recurrence. Due to the severity of this condition, ethical constraints mean that most trials do not use a placebo, and regulatory reviews note that some older RCTs have a High Risk of Bias in how non-fatal outcomes were assessed.


What is Still Uncertain About Lactulose Research

The body of research highlights what is known and what is still uncertain about the compound's use. There is limited information for long-term outcomes and durability of response beyond the immediate treatment or prophylaxis periods. Subgroup findings are uncertain in many areas due to modest sample sizes or the exclusion of patients with complex conditions, meaning the results apply only to the populations studied within the clinical trials.

Key Studies & References Management of Functional Constipation in Children and Young People: NICE Guideline CG99

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lactulose - 1 A Pharma (FAQ)

Q: Can I take Lactulose before or after a meal?

Official regulatory documents indicate that Lactulose may be taken with or without food. If a single dose is taken each day, it is generally recommended to take it at the same time daily to support consistent use.

Q: How should I dispose of the leftover Lactulose solution?

Official guidance states that unused or expired Lactulose solution should not be disposed of in household waste or via wastewater (e.g., flushing it down the toilet or sink). The product must be disposed of in accordance with the specific local requirements for pharmaceutical waste.

Q: Is there a maximum number of days I should take Lactulose for constipation?

Official product information discourages the unsupervised, long-term use of laxatives for constipation. For certain patient groups, such as the elderly or debilitated, the labeling specifies that periodic checks of serum electrolytes (like potassium) are indicated if treatment continues for more than six months.

Q: What are the symptoms of an overdose of Lactulose?

Symptoms reported in regulatory documents following a Lactulose overdose are primarily related to the digestive system, including diarrhea and abdominal cramps. Prolonged, high-dose exposure carries the risk of electrolyte loss (an imbalance of salts in the body). A suspected overdose is considered a medical event and requires attention.

Q: Does Lactulose contain any sugar that affects my diabetes?

Lactulose is a synthetic sugar, and the solution may contain minor amounts of other related sugars, such as lactose, galactose, and fructose, which are remnants from the manufacturing process. The labeling notes that special caution is required for patients with Diabetes Mellitus when high doses, such as those used for Hepatic Encephalopathy (HE), are administered.

Q: What should I do if I forget a dose of Lactulose?

Official patient information states that a missed dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. The schedule should be resumed thereafter. It is specified that a double dose should not be taken to compensate for a missed dose.

Advertisements

How should Lactulose - 1 A Pharma be stored and disposed of?

How to Store and Dispose of Lactulose Solution

The storage and disposal requirements for lactulose oral solution are defined by regulatory agencies to ensure product stability and safety.


Official Storage and Handling

Lactulose solution must be stored at controlled room temperature, typically 20^circ to 25 C (68^circ to 77 F), and must be protected from direct light.

Condition Requirement
Temperature Do not freeze or expose to temperatures above 30 C.
Container Keep the container tightly closed and in its original or a light-resistant container.
Stability Extreme darkening or turbidity indicates the product should not be used.
Child Safety Keep out of the sight and reach of children.

Disposal Requirements

Unused or expired lactulose solution must be disposed of in accordance with local requirements for pharmaceutical waste. Do not discard medicines via wastewater or household waste to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lactulose - 1 A Pharma found in:

A-Z Index: